Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032
... be psychologically devastating. Alopecia areata is clinically heterogeneous, and the course of the disease is unpredictable, with spontaneous regrowth of hair occurring in 80% of patients within the first year and sudden relapse at any ... Read More
-
Blockchain in Drug Discovery and Clinical Trials Market, 2023-2035
... drugs and other pharmaceutical products, thereby reducing the prevalence of counterfeit drugs and medicine. The drug discovery process, which involves the identification of a relevant biological target and a corresponding pharmacological lead, is deemed crucial ... Read More
-
Retinopathy of Prematurity - Market Insight, Epidemiology And Market Forecast - 2032
... most important risk factor for developing Retinopathy of Prematurity is the baby’s age and weight at birth. Especially children with gestational age at birth below 31 weeks or a birth weight of less than 1,500 ... Read More
-
Dupilumab Emerging Drug Insight and Market Forecast − 2032
... of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
-
X0002 Emerging Drug Insight and Market Forecast − 2032
... the X0002 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
Arbaclofen ER Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the Arbaclofen ER for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided ... Read More
-
FLUCELVAX QUADRIVALENT Drug Insight and Market Forecast − 2032
... picture of the FLUCELVAX QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this ... Read More
-
FLUZONE QUADRIVALENT Drug Insight and Market Forecast − 2032
... picture of the FLUZONE QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this ... Read More
-
YG1699 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the YG1699 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
Diamyd Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the diamyd for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
Pozelimab Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the pozelimab for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
Cyclin-Dependent Kinase Inhibitor- Pipeline Insight, 2023
... profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered ... Read More
-
Primary Biliary Cholangitis - Pipeline Insight, 2023
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
-
Global Visceral Leishmaniasis Treatment Market - 2023-2030
... the forecast period 2023-2030. The global visceral leishmaniasis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Over 95% of cases of visceral leishmaniasis (VL), often known ... Read More
-
MesoPher Drug Insight and Market Forecast − 2032
... of the MesoPher for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report ... Read More
-
Regorafenib Drug Insight and Market Forecast − 2032
... the regorafenib for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along ... Read More
-
K-321 Emerging Drug Insight and Market Forecast − 2032
... A detailed picture of the K-321 for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided ... Read More
-
Netarsudil Emerging Drug Insight and Market Forecast − 2032
... A detailed picture of the netarsudil for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided ... Read More
-
RTX Emerging Drug Insight and Market Forecast − 2032
... the RTX for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
Liposomal Cyclosporine A Emerging Drug Insight and Market Forecast − 2032
... in the seven major markets. A detailed picture of the liposomal cyclosporine A for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and ... Read More
-
LEVEMIR Drug Insight and Market Forecast − 2032
... of the LEVEMIR for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided ... Read More
-
ONC201 Emerging Drug Insight and Market Forecast − 2032
... picture of the ONC201 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
-
Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032
... is a localized form of prostate cancer. When prostate cancer is diagnosed at this stage, it means that cancer cells are confined to the prostate and have not yet invaded surrounding tissues or metastasized (spread) ... Read More
-
LNP023 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the LNP023 for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
INO-5401 + INO-9012 + LIBTAYO Emerging Drug Insight and Market Forecast − 2032
... LIBTAYO for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the INO-5401+ INO-9012 + LIBTAYO for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and ... Read More
Research Assistance
